Clinical Trial Update: UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients [Phase 3]

View source ↗

Summary

Phase 3 study of Velcade, thalidomide, and dexamethasone with or without Adriamycin in relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Adriamycin (doxorubicin)
• DEXAMETHASONE (Dexamethasone)
• Thalomid (thalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED